Takashi Shimada
President chez PHOENIXBIO CO., LTD.
Fortune : 109 498 $ au 30/04/2024
Profil
Takashi Shimada is currently the Chairman at KMT Hepatech, Inc. and the Chairman at PhoenixBio USA Corp.
He is also the President & Representative Director at PhoenixBio Co., Ltd.
In the past, he worked as the Director & Administration Manager at Institute of Immunology Co., Ltd.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PHOENIXBIO CO., LTD.
0,90% | 31/03/2023 | 36 200 ( 0,90% ) | 109 498 $ | 30/04/2024 |
Postes actifs de Takashi Shimada
| Sociétés | Poste | Début |
|---|---|---|
| PHOENIXBIO CO., LTD. | President | 28/06/2018 |
PhoenixBio USA Corp.
 PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Part of PhoenixBio Co., Ltd., PhoenixBio USA Corp. develops technologies for mass propagation of human cells into laboratory animals. The company is based in New York, NY. Yoshio Morikawa has been the CEO of the company since 2015. | Président | 01/06/2018 |
KMT Hepatech, Inc.
 KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services KMT Hepatech, Inc. provides vivo research services focusing on preclinical development of Hepatitis C, Hepatitis B, and Malaria therapeutics and vaccines. It offers scientific evaluation services for drug metabolism, lipoprotein metabolism, dose response, and drug treatment. The firm provides KMT Mouse, a transgenic mouse model for practical testing of HCV drug candidates. The company was founded by Norman Miles Kneteman, David F. Mercer and David Lorne John Tyrrell in 2001 and is headquartered in Edmonton, Canada. | Président | 01/12/2017 |
Anciens postes connus de Takashi Shimada
| Sociétés | Poste | Fin |
|---|---|---|
Institute of Immunology Co., Ltd.
 Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Directeur Administratif | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHOENIXBIO CO., LTD. | Commercial Services |
| Entreprise privées | 3 |
|---|---|
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Health Technology |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Part of PhoenixBio Co., Ltd., PhoenixBio USA Corp. develops technologies for mass propagation of human cells into laboratory animals. The company is based in New York, NY. Yoshio Morikawa has been the CEO of the company since 2015. | Commercial Services |
KMT Hepatech, Inc.
KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services KMT Hepatech, Inc. provides vivo research services focusing on preclinical development of Hepatitis C, Hepatitis B, and Malaria therapeutics and vaccines. It offers scientific evaluation services for drug metabolism, lipoprotein metabolism, dose response, and drug treatment. The firm provides KMT Mouse, a transgenic mouse model for practical testing of HCV drug candidates. The company was founded by Norman Miles Kneteman, David F. Mercer and David Lorne John Tyrrell in 2001 and is headquartered in Edmonton, Canada. | Commercial Services |